CORT — Corcept Therapeutics Incorporated price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $70.07
- YTD price return
- +101.35%
- YTD total return
- +101.35%
- Market cap
- 7.7B
- Enterprise value
- 7.3B
- Shares outstanding
- 109.4M
- 52W low
- $28.66
- 52W high
- $126.38
- From 52W high
- -44.56%
- From 52W low
- +144.49%
- 52W range
- 42%$28.66–$126
- Beta
- 0.45
Volume
- Rel volume
- 0.89×
- 30D volume
- 1.1M
- 30D $ vol
- 96.4M
Insider trading
- Insider net 1W
- −$727K
- Insider net 1M
- −$3.6M
- Insider net 3M
- −$28.5M
- Insider net 1Y
- −$87.9M
Form 4 transactions by trade date, as filed; latest on file 2026-11-13.
Fundamentals
- Sales (ttm)
- 963.6M
- Sales/share
- $8.81
- EPS (ttm)
- $1.39
- FCF (ttm)
- 194.6M
- FCF/share
- $1.78
- Book value/share
- $7.62
- Net margin
- 16.84%
- ROE
- 19.47%
- ROA
- 15.70%
- Current ratio
- 3.00
Growth (CAGR, ttm) · 10Y
- Sales
- +30.04%+28.88%+22.26%+28.87%
- Net income
- +52.99%+21.09%+8.80%+43.12%
- FCF
- +19.18%+8.03%+4.97%+26.97%
- Shares
- +4.05%+2.02%-1.06%-0.14%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +57.24%+19.91%+10.91%+42.64%
- Sales/share
- +24.98%+26.34%+23.57%+29.29%
- FCF/share
- +14.54%+5.89%+6.10%+27.15%
- Book value/share
- +26.83%+19.36%+10.24%+39.08%
- Price
- -6.73%+39.31%+24.77%+22.17%
- Total return
- -6.73%+39.31%+24.77%+22.17%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 50.3×
- P/OI (ttm)
- 69.1×
- Fwd P/E
- 14.1×
- P/S (ttm)
- 8.0×
- P/B (mrq)
- 9.2×
- P/FCF (ttm)
- 39.4×
- EV/EBITDA (fy)
- 64.3×
- EV/Sales (ttm)
- 7.6×
- FCF yield (ttm)
- 2.54%
- Buyback yield (realized, 1y)
- -4.05%
- Shareholder yield (realized, 1y)
- -4.05%
- Buyback yield (cash, ttm)
- 0.07%
- Shareholder yield (cash, ttm)
- 0.07%
Vs own 10Y history
- P/E
- 74th
- P/OI
- 80th
- P/S
- 69th
- P/B
- 71st
- P/FCF
- 75th
Bar = where today’s multiple sits in CORT’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-17#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y CAGR −19.0%10Y n/mYoY +1022.7%EPS (diluted)
5Y CAGR −0.7%10Y n/mYoY +531.3%Free cash flow
5Y CAGR −1.2%10Y CAGR +46.5%YoY +161.0%TTM: operating cash flow $198.1M, capex −$3.5M
Q3 2026: operating cash flow $142.9M, capex −$709K
Shares (diluted)
5Y −3.4%10Y +12.3%YoY +3.1%Net income
5Y CAGR −1.2%10Y n/mYoY +544.6%About Corcept Therapeutics#
Data provided bySource: Twelve DataCorcept Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that modulate cortisol activity to address serious endocrine, oncologic, metabolic, and neurologic disorders. Its commercial portfolio is centered on Korlym, an oral therapy used for adults with endogenous Cushing’s syndrome and related hypercortisolism. The company also advances a pipeline of selective cortisol modulators across multiple therapeutic areas, including relacorilant for Cushing’s syndrome and certain cancers, Lifyorli for oncology, and other investigational programs in metabolic disease and amyotrophic lateral sclerosis. Corcept Therapeutics serves the specialized rare-disease and specialty-pharmaceutical markets, where its products and research are aimed at conditions with limited treatment options. The company is headquartered in Redwood City, California.
Redwood City, CA·730 employees·Biotechnology·corcept.com·As of Oct 28, 2026
Recent filings#
- Nov 3Earnings · Earnings release — EPS $1.01 vs $0.68 est. (+48.5%); revenue $340.5M (+64% y/y) 3.3%
- Sep 238-K · Corcept Announces Planned Leadership Transition
- Aug 26Insider sale · Park Kimberly (Director) sold 26,685 shares for $3.3M at $122.55
- Aug 17Insider sale · Robb Gary Charles (Chief Business Officer) sold 10,000 shares for $1.2M at $116.26
- Aug 3Insider sale · Lyon Joseph Douglas (See Remarks) sold 1,540 shares for $176K at $114.16
ETFs holding CORT#
19 of the 193 ETFs ChartRow carries live hold CORT. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| VIOO | Vanguard S&P Small-Cap 600 ETF | 0.6% |
| IJR | iShares Core S&P Small-Cap ETF | 0.4% |
| IWP | iShares Russell Mid-Cap Growth ETF | 0.2% |
| VBK | Vanguard Small-Cap Growth ETF | 0.2% |
| VHT | Vanguard Health Care ETF | 0.2% |
| VXF | Vanguard Extended Market ETF | 0.1% |
| VB | Vanguard Small-Cap ETF | 0.1% |
| IWR | iShares Russell Midcap ETF | 0.1% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |
